CD274 and head and neck squamous cell carcinoma: This observation has been endorsed by the KEYNOTE-040 and -048 trials in R/M HNSCC where survival in PD-L1 expressing cases was significantly increased (Burtness et al., 2019; Cohen et al., 2019).